Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction

https://doi.org/10.1016/S0002-9149(97)89176-XGet rights and content

We have directly compared atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and N-terminal pro-ANP (N-ANP) as markers of patients with left ventricular ejection fraction (LVEF) ≤35%, as measured by radionuclide ventriculography. Venous blood samples were obtained from an unselected group of 87 patients who had been referred for assessment of ventricular function. ANP, BNP, and N-ANP were measured by radioimmunoassay using commercial kits. Receiver-operating characteristic analysis was used for the objective assessment of the diagnostic performance of each assay. There was a weak negative correlation between LVEF and plasma levels of ANP-li (r = −0.50,), BNP-li (r =−0.57), and N-ANP-li (r = −0.49) (p <5.01 for each peptide). Areas under the receiver-operating characteristic curves for BNP (0.880) and N-ANP (0.832) were not significantly different from each other, but were both significantly greater than the value for ANP (0.761): BNP versus ANP, p <0.01; and N-ANP versus ANP, p <0.05. The optimal sensitivity and specificity of each assay for the detection of patients with LVEF ≤35% were: BNP >4 pmol/L—sensitivity 1.0, specificity 0.58; N-ANP >200 pmol/L—sensitivity 0.95, specificity 0.35; and ANP >10 pmol/L—sensitivity 0.90, specificity 0.30. Plasma concentrations of BNP and N-ANP provide sensitive indicators of moderate to severe LV dysfunction; both peptides are objectively superior to ANP for identifying patients with LVEF ≤35%. These simple tests could be used to screen patients with suspected ventricular dysfunction to reduce the demand for further cardiac investigations.

References (9)

  • LermanA et al.

    Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction

    Lancet

    (1993)
  • YasueH et al.

    Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure

    Circulation

    (1994)
  • NakaoK et al.

    Molecular biology and biochemistry of the natriuretic peptide system I: natriuretic peptides

    J Hypertens

    (1992)
  • YandleTG et al.

    Assay of brain natriuretic peptide (BNP) in human plasma: evidence for a high molecular weight BNP as a major plasma component in heart failure

    J Clin Endocrinol Metab

    (1993)
There are more references available in the full text version of this article.

Cited by (186)

  • Radiation-induced cardiac damage in early left breast cancer patients: Risk factors, biological mechanisms, radiobiology, and dosimetric constraints

    2012, Radiotherapy and Oncology
    Citation Excerpt :

    It could be a useful tool in the evaluation of modern RT techniques, with respect to cardiac toxicity [37]. As LVEF values decreased in patients with left ventricular dysfunction or coronary artery disease [94,95], Perik et al., in the previously mentioned study, determined LVEF through radionuclide ventriculography and natriuretic peptide plasma concentrations in RT- and chemotherapy (CHT) – treated patients with left breast cancer. After a median of 2.7 years following chemotherapy and chest wall irradiation, subnormal LVEF values were observed in about 13% of the 54 patients examined [92].

  • Chronic Cardiac Failure

    2010, Brocklehurst's Textbook of Geriatric Medicine and Gerontology
View all citing articles on Scopus
1

Dr. Davidson was supported by a grant from the British Heart Foundation, London, United Kingdom.

View full text